Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Teleste: Interim Report Q3 2019 will be published on October 31st - Invitation to press briefing

TELESTE CORPORATION       INVESTOR NEWS        24.10.2019    AT 10:00 EET TELESTE: INTERIM REPORT Q3 2019 WILL BE PUBLISHED ON OCTOBER 31st - INVITATION TO PRESS BRIEFING Teleste will publish its Interim Report 1 January – 30 September 2019 as a stock exchange release on October 31st approx. at 08:30 a.m. EET. A briefing for investors, media and analysts and will be held the same day in Helsinki hosted by CEO, Mr. Jukka Rinnevaara. Teleste's CFO, Mr. Juha Hyytiäinen will also be present in the briefing.  PRESS BRIEFING (held in Finnish):Date: Thursday, October 31st 2019

Super dynamic tension springs in next generation’s trampoline

In order to provide the best possible trampoline experience, tension springs  with ultimate properties are required. North Trampoline has, assisted by Lesjöfors, developed a premium product with the exact firmness and a long lifespan, that professional jumpers call "world class".In North Trampoline’s development process of the Performer Revolution  for jumpers with higher demands on performance, quality and safety, the existing spring solution needed to be refined and improved. Therefore, in 2018

UPM Interim Report Q3/2019: UPM reports good performance and strong financial position – Uruguay decision drives significant future earnings growth

UPM-Kymmene Corporation                   Interim Report               24 October 2019 at 09:55 EET UPM Interim Report Q3/2019: UPM reports good performance and strong financial position – Uruguay decision drives significant future earnings growth Q3 2019 highlights · Sales decreased by 6% to EUR 2,493 million (2,650 million in Q3 2018) · Comparable EBIT decreased by 19% to EUR 342 million (420 million) · Sales prices decreased in pulp, outweighing the impact of lower variable costs in all business areas · UPM announced the transformative investment in Uruguay for

Vator Securities: AlzeCure Pharma - A win for the amyloid hypothesis is a win for AlzeCure

Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case. The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta. It also offers several advantages over some of the more advanced peers such as BioArctic’s BAN2401 and Biogen’s aducanumab. We expect that future progress and generation of satisfactory data will drive the stock price and trigger an elevated company valuation. Läs mer och ladda ned analysen:

Follicum receives Eurostars grant to develop the company's first-in-class treatment of diabetes

Follicum today announces that the company’s application for a Eurostars grant comprising the development of a first-in-class treatment for diabetes has been approved. Follicum is the coordinator of the project. Other partners include Lund University, Bioassay Labor für biologische Analytik GmbH and Deutsche Diabetes-Forschungsgesellschaft (DDZ).The grant comprising just under EUR 0.7 M commences December 1, 2019 and provides additional resources for the Company's development of a peptide-based treatment of diabetes. Follicum, together with other partners in the consortium, will study

Interim Report, January - September 2019

Period July 1 – September 30, 2019 · Net sales of SEK 92.4 m (SEK 95.6 m) · Software revenues of SEK 66.1 m (SEK 64.8 m) · Recurring revenues of SEK 61.4 m (SEK 56.3 m) which corresponds to 66 % (59 %) of net sales. · EBITDA SEK 24.3 m; 26.3 % (SEK 25.6 m; 26.8 %) · EBITDA-adj. SEK 14.5 m; 15.7 % (SEK 16.9 m; 17.7 %) · EBIT SEK 11.2 m; 12.1 % (SEK 13.9 m; 14.5 %) · Net profit SEK 8.3 m; 8.9 % (SEK 10.1 m; 10.6 %) · EPS before dilution SEK 0.16 (SEK 0.19) · Cash flow from operating activities SEK 21.5 m (SEK 19.9 m) Period January 1 – September 30, 2019 ·

Inhalation Sciences technology spotlighted by researchers at 4 major industry events

From Austria to Sweden to California to the UK: October has been an intensive month for Inhalation Sciences' flagship aerosol generator PreciseInhale. It has been spotlighted by senior ISAB clients such as Fraunhofer ITEM at four global industry events. “Customers of this calibre sharing the findings they’re achieving really underlines the strategic value we deliver” says ISAB CEO Manoush Masarrat.PreciseInhale has been presented at four different inhalation events in October, each time by clients showcasing specific benefits and findings they got from the system. “The range of events

Archer Limited: Announcement of third quarter 2019 earnings release date and conference call information

Hamilton, Bermuda (October 24, 2019) Archer Limited's third quarter 2019 earnings are scheduled to be released on November 6, 2019 before the start of trading on Oslo Stock Exchange.  In connection with the earnings release, a conference call will be held at 8:00am London time, 9:00am Oslo time on November 6, 2019. To listen to the conference call, the following options are available: A. Webcast To register for the webcast please go to https://archer.eventcdn.net/2019q3/   B. Conference call To access the call, which is open to the public, please contact the conference

Breakthrough: ExpreS2ion launches first unique cell line for enhanced efficacy of vaccines and immunotherapy

After several years of research and development, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the launch of a new tailormade S2 cell line, HighMan-S2™. This is the first member of ExpreS2ion’s new functionally modified S2 product line, GlycoX-S2™, which utilises and expands the advantages of the ExpreS2 platform.For several years, ExpreS[2]ion has been working on the development of adding functional modifications to its powerful ExpreS[2] platform. This makes the introduction of the new HighMan-S2™ cell line an important

AR Packaging to launch fibre-based cutlery in cooperation with Bionatic

AR Packaging aims to meet the increasing need for replacement of plastic-based cutlery and has teamed up with the food service distributor Bionatic to launch a fibre-based cutlery range.Since the European Single-Use Plastics Directive (SUP) was introduced, both consumers and member states have started to reconsider many plastic packaging items on the market. By 2021, plastic cutlery will be banned in the EU. While targeting some of the issues related to unrecyclable items and potential littering, the demand for eating on-the-go will remain. There is therefore a great need for a new

Change in Eltel Management Team – CFO Petter Traaholt to leave Eltel

Petter Traaholt, Chief Financial Officer (CFO) of Eltel, will leave the company to assume the position as CFO at V.Group, the leading ship management and marine services provider based in London. A search process for his successor will start immediately.Petter Traaholt will continue in his position until end of February 2020. – During his time with the company, Petter has, together with the management team, been instrumental in the ongoing transformation of the business. Over the past years, we have de-risked the company, restructured the business into a country-based organization, re-

PowerCell launches its Chinese subsidiary

PowerCell Sweden AB (publ) has received all permits needed to establish its Chinese subsidiary, PowerCell Fuel Cell (Shanghai) Co Ltd. The office will be located in Shanghai where recruitment of local employees has started.Yibo Zhao, responsible for Sales area Asia has been appointed as manager of PowerCell Fuel Cell (Shanghai) Co Ltd. Mr Zhao has been with PowerCell since 2017 and has previously worked for Frontpac, where he was a sales representative in China, and the Volvo Group. The recruitment of local employees is currently underway. China has over the last couple of years introduced

Report on Operations 2018-2019: Strategic acquisition and strong closing of the year

CELLINK publishes the quarterly report for the period 1[st ]of June 2019 – 31[st] of August 2019 and for the full year of operations 2018-2019. The report is available on the company's website: https://cellink.com/investors/ This press release presents a summary of the report. Fourth quarter · Net sales amounted to SEK 31,997 (16,465) thousand, corresponding to a growth of 94%, of which 23% was organic growth, compared to the fourth quarter of the previous fiscal year. · Operating profit before depreciation (EBITDA) amounted to SEK -2,435 (1,069) thousand, corresponding to a

Swedencare AB (publ) INTERIM REPORT JULY 1ST – SEPTEMBER 30TH 2019

32% growth yielded new profit recordSUMMARY OF THE PERIOD THIRD QUARTER: JULY 1ST – SEPTEMBER 30TH 2019 Numbers in parentheses refers to outcomes during the corresponding period of the previous year. · Net revenue amounted to 31,759 KSEK (24,005 KSEK), an increase of 32%  · Organic, currency-adjusted growth amounted to 15%  · Operating profit before depreciation (EBITDA) amounted to 11,311 KSEK (8,842 KSEK), corresponding to an increase of 28% and an EBITDA margin of 35,6% (36.7%)  · Operating profit after depreciation (EBIT) amounted to 10,995 KSEK (8,664 KSEK),

Interim report January to September 2019

Profitable integration with high growth Third quarter · Net sales increased during the third quarter by 88,1% to 82,4 MSEK (43,8) · Adjusted EBITDA amounted to 8,5 MSEK (3,2), corresponding to a margin of 10,4% (7,3) · EBITDA for the third quarter amounted to 4,3 MSEK (3,2), corresponding to a margin of 5,2% (7,3) · Net result after tax was -13,0 MSEK (0,1) whereof amortizations of goodwill in accordance with the standard accounting principles (K3) applied by TagMaster amounted to -9,6 MSEK · Result per share was -0,04 (0,00) · Cash flow from operating activities

Heliospectra to Partner with Nectar Farms on MITRA LED Lighting Solutions for Large Scale Glasshouse Installation in Australia

(GOTHENBURG, Sweden / TORONTO, Canada / TOKYO, Japan / SAN FRANCISCO, CA, October 24, 2019) – Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH GROWTH MARKET: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, announces a new order for MITRA LED lighting solutions from Nectar Farms in Victoria, Australia. The order value is SEK 72 million and includes a down payment of 50 percent during Q4 2019. The production will not be initiated until Heliospectra receives the down payment. Revenue is expected during the second and third

AAK’s Interim report for the third quarter 2019 – continued profit growth on the back of a strong Food Ingredients performance

AAK Group · Total volumes for the quarter amounted to 571,000 MT (564,000), organic growth of 1 percent (4). · Operating profit, including a positive currency translation impact of SEK 24 million and acquisition costs of SEK 6 million, reached SEK 563 million (526), an improvement of 7 percent. Excluding acquisition costs, operating profit per kilo improved by 8 percent to SEK 1.00 (0.93). · Net result amounted to SEK 398 million (359), an improvement of 11 percent. · Earnings per share increased by 10 percent, to SEK 1.53 (1.39). · Cash flow from operating

Interim report Q2 1 April - 30 September 2019

Second quarter (1 July - 30 September 2019) · Net sales increased by 25 percent and amounted to SEK 2,917 million (2,338). · Operating profit before amortisation of intangible non-current assets (EBITA) increased by 41 percent and amounted to SEK 380 million (270) corresponding to an EBITA margin of 13.0 percent (11.5).  · Operating profit increased by 45 percent and amounted to SEK 329 million (226) corresponding to an operating margin of 11.2 percent (9.7). · Profit after tax increased by 37 percent and amounted to SEK 240 million (174) and earnings per share before dilution

Interim report January-September 2019

Collector AB publishes Interim report for the period January-September 2019THIRD QUARTER 2019 (COMPARED TO THE THIRD QUARTER OF 2018) • The loan portfolio increased by 32% to SEK 30,577 million (23,124) • Total income increased by 21% to SEK 544 million (450) • The C/I ratio amounted to 41.5% (43.4) • The credit loss level amounted to 1.4% (1.1) • Net profit increased by 7% to SEK 164 million (153) • Return on equity amounted to 16.9% (18.9) • Earnings per share amounted to SEK 1.60 (1.49) JANUARY–SEPTEMBER 2019 (COMPARED TO JANUARY–SEPTEMBER 2018) • The loan

SaltX pilot will be built and financed by new Chinese partner

– Shuangliang will build and develop an energy storage pilot in China  The energy storage company SaltX Technology – listed on Nasdaq First North Premier Growth Market – enters an agreement with Shuangliang Boiler Co., Ltd (Shuangliang). The Chinese partner will build and finance a pilot plant to commercialize SaltX energy storage technology on the Chinese market. The parties have agreed on a first pilot project commissioned in 2020. The pilot is an energy storage unit that will be charged with electric power and discharge steam. The pilot will be based on learnings from the

Citycon’s Financial Reporting Schedule and AGM in 2020

CITYCON OYJ   Stock Exchange Release   24 October 2019 at 09:05 hrsCitycon Oyj’s schedule of the financial reporting in 2020 is the following: Year 2019 full-year Financial Thursday 6 February 2020 at about 9:00 a.m.Report, Financial Statements andthe Report by the Board ofDirectorsYear 2020 three-month Interim Thursday 23 April 2020 at about 9:00 a.m.ReportYear 2020 six-month Half-Yearly Friday 10 July 2020 at about 9:00 a.m.ReportYear 2020 nine-month Interim Thursday 15 October 2020 at about 9:00 a.m.Report Citycon Oyj’s Annual General Meeting (AGM)

InDex Pharmaceuticals presents today at Redeye Investor After Work

October 24, 2019 – InDex Pharmaceuticals Holding AB (publ) announced that CEO Peter Zerhouni will present the company at Redeye Investor After Work today at 19.30 CET at Scandic Rubinen, Kungsportsavenyen 24, in Gothenburg. The presentation will be livestreamed and can be followed at https://www.redeye.se/live/inv-aw-gbg-24-10.The presentation will also be available afterwards on the company’s page in Redeye Universe (www.redeye.se/company/index-pharmaceuticals), as well as on the company’s website (www.indexpharma.com).   For more information:Peter Zerhouni, CEOPhone: +46 8 508

Asarina Pharma has completed a directed share issue of approximately SEK 48 million

Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces that the Company has successfully completed a directed share issue of 2,159,148 shares, corresponding to approximately SEK 48 million. In addition, existing shareholders have due to high demand sold 764,329 existing shares, corresponding to approximately SEK 17 million, in connection with the issue. The issue was subscribed for by a few institutional investors, including the Fourth AP Fund, Swedbank Robur, Östersjöstiftelsen and Handelsbanken.The board of directors of

Quarterly Report July - September 2019 Everysport Media Group AB (publ)

Results continue to improveThis is a translated version of the Swedish original, in case of deviations is the Swedish version considered to be the one to apply. This information is such information that Everysport Media Group AB (publ.) Is required to publish in accordance with the EU Market Abuse Regulation.The information was provided, through the agency of the above contact person, for publication on October 24th, 2019. Summary of the third quarter 2019 • Net sales: 21,0 mkr (20,6 mkr) • EBITDA: 2,7 mkr (2,3 mkr) • Profit after tax -0,7 mkr (-1.0 mkr) • Earnings per

There are no items matching the current filter
There are no more items matching the current filter
Back to top